posted on 2023-05-20, 11:11authored byKonttinen, H, Cabral-da-Silva, MeC, Ohtonen, S, Wojciechowski, S, Shakirzyanova, A, Caligola, S, Giugno, R, Ishchenko, Y, Hernandez, D, Fazaludeen, MF, Eamen, S, Budia, MG, Fagerlund, I, Scoyni, F, Korhonen, P, Huber, N, Haapasalo, A, Alexander HewittAlexander Hewitt, James VickersJames Vickers, Smith, GC, Oksanen, M, Graff, C, Kanninen, KM, Lehtonen, S, Propson, N, Schwartz, MP, Pebay, A, Koistinaho, J, Ooi, L, Malm, T
Here we elucidate the effect of Alzheimer disease (AD)-predisposing genetic backgrounds, APOE4, PSEN1ΔE9, and APPswe, on functionality of human microglia-like cells (iMGLs). We present a physiologically relevant high-yield protocol for producing iMGLs from induced pluripotent stem cells. Differentiation is directed with small molecules through primitive erythromyeloid progenitors to re-create microglial ontogeny from yolk sac. The iMGLs express microglial signature genes and respond to ADP with intracellular Ca2+ release distinguishing them from macrophages. Using 16 iPSC lines from healthy donors, AD patients and isogenic controls, we reveal that the APOE4 genotype has a profound impact on several aspects of microglial functionality, whereas PSEN1ΔE9 and APPswe mutations trigger minor alterations. The APOE4 genotype impairs phagocytosis, migration, and metabolic activity of iMGLs but exacerbates their cytokine secretion. This indicates that APOE4 iMGLs are fundamentally unable to mount normal microglial functionality in AD.
History
Publication title
Stem Cell Reports
Volume
13
Issue
4
Pagination
669-683
ISSN
2213-6711
Department/School
Menzies Institute for Medical Research
Publisher
Cell Press
Place of publication
United States
Rights statement
Copyright 2019 The Authors. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/